Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anterior Petrosectomy With Intertentorial Approach.
Starnoni D, Peters D, Giammattei L, Fava A, Cadas H, Schranz S, Sabatasso S, Messerer M, Daniel RT. Starnoni D, et al. Among authors: schranz s. Oper Neurosurg (Hagerstown). 2024 Mar 1;26(3):301-308. doi: 10.1227/ons.0000000000000966. Epub 2023 Oct 25. Oper Neurosurg (Hagerstown). 2024. PMID: 37878474 Free PMC article.
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.
Mayer KA, Schrezenmeier E, Diebold M, Halloran PF, Schatzl M, Schranz S, Haindl S, Kasbohm S, Kainz A, Eskandary F, Doberer K, Patel UD, Dudani JS, Regele H, Kozakowski N, Kläger J, Boxhammer R, Amann K, Puchhammer-Stöckl E, Vietzen H, Beck J, Schütz E, Akifova A, Firbas C, Gilbert HN, Osmanodja B, Halleck F, Jilma B, Budde K, Böhmig GA. Mayer KA, et al. Among authors: schranz s. N Engl J Med. 2024 Jul 11;391(2):122-132. doi: 10.1056/NEJMoa2400763. Epub 2024 May 25. N Engl J Med. 2024. PMID: 38804514 Clinical Trial.
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
Mayer KA, Budde K, Halloran PF, Doberer K, Rostaing L, Eskandary F, Christamentl A, Wahrmann M, Regele H, Schranz S, Ely S, Firbas C, Schörgenhofer C, Kainz A, Loupy A, Härtle S, Boxhammer R, Jilma B, Böhmig GA. Mayer KA, et al. Among authors: schranz s. Trials. 2022 Apr 8;23(1):270. doi: 10.1186/s13063-022-06198-9. Trials. 2022. PMID: 35395951 Free PMC article.
Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism.
Mühlbacher J, Schörgenhofer C, Doberer K, Dürr M, Budde K, Eskandary F, Mayer KA, Schranz S, Ely S, Reiter B, Chong E, Adler SH, Jilma B, Böhmig GA. Mühlbacher J, et al. Among authors: schranz s. Transpl Int. 2021 Aug;34(8):1542-1552. doi: 10.1111/tri.13954. Epub 2021 Jul 8. Transpl Int. 2021. PMID: 34153143 Free PMC article. Clinical Trial.
A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, Reeve J, Borski A, Kozakowski N, Reindl-Schwaighofer R, Waiser J, Lachmann N, Schranz S, Firbas C, Mühlbacher J, Gelbenegger G, Perkmann T, Wahrmann M, Kainz A, Ristl R, Halleck F, Bond G, Chong E, Jilma B, Böhmig GA. Doberer K, et al. Among authors: schranz s. J Am Soc Nephrol. 2021 Mar;32(3):708-722. doi: 10.1681/ASN.2020071106. Epub 2020 Dec 18. J Am Soc Nephrol. 2021. PMID: 33443079 Free PMC article. Clinical Trial.
14 results